ATNMActinium Pharmaceuticals, Inc.

Sign up free
ChallengedLast material event Aug 14, 2026 · Updated Oct 25, 2026

Actinium rebuilt its equity, but Actimab-A has no dated results

Actinium Pharmaceuticals develops targeted radiation therapies for cancer, led by Actimab-A for acute myeloid leukemia; none is approved.

Actinium's case rests on Actimab-A, an actinium-225 antibody against CD33, which the company says improved survival with CLAG-M chemotherapy in relapsed or refractory AML. It is advancing toward a Phase 2/3 trial and runs further studies with the National Cancer Institute, with milestones expected from late 2026 into 2027. ATNM-400 for solid tumors is still preclinical. Cash was $36.5 million at June 30, which Actinium says lasts more than 12 months.

Thesis checklist

1 risk needs attention

Select a row for evidence
Actimab-A moves into a Phase 2/3 trialAwaiting evidenceNext: A Phase 2/3 start or new study data.

Why it is in this state

The evidence, what would weaken it and the source filing

ATNM-400 reaches patientsAwaiting evidenceNext: An IND filing or first patient dosed; timing not yet disclosed.

Why it is in this state

The evidence, what would weaken it and the source filing

Actinium keeps its NYSE American listingAt riskNext: NYSE American confirmation that Actinium complies.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts until the next milestonesSupportedNext: Third-quarter cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Actimab-A clinical milestones

Tests: Actimab-A moves into a Phase 2/3 trial

Second half of 2026 through 2027

Do the NCI and company studies of Actimab-A produce data or a Phase 2/3 start in this period?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentCorporate
Aug 14, 2026

Actinium rebuilt its equity, but Actimab-A has no dated results

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Acute myeloid leukemia· relapsed/refractory
Actimab-A · 1 upcoming
Phase 2/3 Study InitiationPivotal
TBD
Acute myeloid leukemia
Actimab-A · 1 upcoming
clinical milestones (CRADA and company-sponsored studies)
2H 2026 – 2027
Other
1 upcoming
Actinium regains NYSE American listing compliance (plan period)
By November 27, 2027

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Other companies we cover in these diseases

Catalyst calendar · Upcoming FDA decisions

Competitive landscape

9 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.